Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases, today ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Management Comments

Adverum Biotechnologies (ADVM) PT Lowered to $4.50 at Chardan Capital MarketsNovember 2, 2018 9:05 AM SunTrust Robinson Humphrey Downgrades Adverum Biotechnologies (ADVM) to HoldNovember 2, 2018 6:23 AM Adverum Biotechnologies Provides Program UpdatesNovember 1, 2018 4:15 PM